logo
  Join        Login             Stock Quote

OncoMethylome Sciences to Perform MGMT Testing in Roche Phase III Study of Avastin for Glioblastoma

Wednesday, January 6, 2010 2:04 AM


Jan. 6, 2010 (Hugin AS) --

OncoMethylome's Technology is being used in Roche Clinical Trial Program with Avastin

 

Liege (Belgium) - January 6, 2010, 8:00 AM CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that it has entered into an agreement with F. Hoffmann-La Roche Ltd., of Basel Switzerland, for MGMT gene promoter methylation testing in a Phase III clinical trial for the use of Avastin in newly diagnosed (glioblastoma [GBM]) brain tumors.

 

This trial will compare the current standard-of-care therapy, which is concurrent chemoradiation and adjuvant temozolomide "TMZ" (TemodarÒ, Schering-Plough), with the standard-of-care plus bevacizumab (AvastinÒ, Roche). All patients will be randomized to TMZ and radiotherapy or TMZ, radiotherapy and bevacizumab. OncoMethylome Sciences will receive payments for performing MGMT testing, using their patented Methylation-Specific PCR (MSP) technology, on all patients enrolled in this trial.

 

As evidenced by this trial, and numerous other Phase II and Phase III clinical trials of new therapies for advanced brain cancers, OncoMethylome's MGMT assay has become the method of choice for determining a patient's MGMT methylation status.  In the future, such information may play a key role in selection of the optimal therapy for each patient. OncoMethylome's MGMT assay is also commercially available in North America through Laboratory Corporation of America (LabCorp) and in Europe through OncoMethylome.

 

Mr. Luc Segers, Senior Director Business Development at OncoMethylome commented, "We are very pleased that MGMT testing will be incorporated into this study, once again demonstrating the market interest in identifying biomarkers that will lead to more personalized healthcare."

 

  

About Glioblastoma Multiforme (GBM) Brain Tumors

GBM is the most aggressive and malignant form of glioma, a type of primary brain tumor. The annual incidence of GBM is four to five cases per 100,000 persons, with 25,000 to 28,000 new cases diagnosed each year in North America and Europe.



Advertisement
Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.